Latest Richard Carl Fuisz Stories
MIAMI, May 22, 2013 /PRNewswire/ -- Fuisz LLC announced today that it has received a notice of allowance in connection with US patent application (serial number 12/874,632) entitled: "Bioactive Dose Having Containing a Material for Modulating pH of a Bodily Fluid to Help or Hinder Absorption of a Bioactive." The allowed claims are directed to a rapid release coating on a tobacco pouch, where the rapid release coating release a buffering agent to modulate the local pH to maximize...
MIAMI, April 22, 2013 /PRNewswire-USNewswire/ -- Fuisz Pharma today announced its intent to divest its strategic issued patent for the detection of opioid abuse (US 7,214,385 "Pharmaceutical Formulation Containing Dye"). This patent covers the use of dyes and staining agents in pharmaceutical dosage forms as a method to prevent the improper use of opioid drugs by visually demonstrating their misuse and abuse. For example, where a patient abuses a drug like oxycodone through nasal...
MIAMI, March 21, 2013 /PRNewswire/ -- Fuisz llc announced the induction of Richard C. Fuisz, M.D., into Georgetown University's 1789 Society. The induction statement, signed by University President Jack DeGioia read as follows: "A prolific inventor, visionary inventor and dedicated philanthropist, Richard C. Fuisz, M.D. (C'61, M'65), has distinguished himself as an alumnus of Georgetown College and Georgetown School of Medicine.... Dr. Fuisz's longstanding support of the...
MIAMI, Jan. 23, 2013 /PRNewswire/ -- Fuisz Pharma LLC announced today that it has received a notice of allowance from the United States Patent and Trademark Office in connection with its utility patent application entitled "Solid Dosage Form That Promotes Reliable Oral, Esophageal and GI Transit" (US 20120141545). The allowed claims cover Fuisz Pharma's new tablet and caplet designs for improved transit, including the tablet that Fuisz Pharma calls the "Saturn(TM)". The Saturn(TM)...
MIAMI, Jan. 16, 2013 /PRNewswire/ -- FUISZ LLC today announced it had filed a patent application with the USPTO for smartphone technology that provides unique advantages and capabilities over those presently in use. Joseph Fuisz, managing member of FUISZ commented: "Despite remarkable advances in smartphone processing power and improving network capabilities, the actual smartphone telephony functionality in use stubbornly refuses to advance. In this new system, we employ a novel...
MIAMI, Jan. 8, 2013 /PRNewswire/ -- Fuisz LLC today announced that it will launch a new oral pre-product in the form of a lozenge in early 2013 designed to enhance tobacco satisfaction from electronic cigarettes, as well as to enhance THC absorption from medical marijuana. The product is protected by a patent pending. Joseph Fuisz, Managing Member of Fuisz, commented, "The extraordinary growth in electronic cigarette consumption at the expense of conventional cigarettes is...
MIAMI, Dec. 20, 2012 /PRNewswire/ -- Fuisz Pharma announced today that it has closed a transaction with MonoSol Rx whereby MonoSol Rx has acquired all rights for United States Patent #8,241,661 and its foreign counterparts. The terms of the sale were not disclosed. Joseph Fuisz Esq., managing member for Fuisz Pharma, explained, "We are pleased to have quickly completed this transaction after a closed bidding process. We are particularly excited that the '661 patent has been...
MIAMI, Dec. 20, 2012 /PRNewswire/ -- Fuisz Pharma LLC today addressed tamper resistance in the context of the Stop Tampering of Prescription Pills Act (STOPP) (H. R. 6160). This law would require the makers of generic opioids to demonstrate comparable tamper-resistance features to the reference, branded opioid tamper-resistant formulations. Richard C. Fuisz, M.D., founding member of Fuisz Pharma (http://en.wikipedia.org/wiki/Richard_Fuisz) commented: "I have been a physician...
MIAMI, Oct. 2, 2012 /PRNewswire/ -- Fuisz Pharma announced today a patented film formulation for enhanced drug delivery performance. The seminal patent for this technology issued as United States Patent 8,241,661 ("Biocompatible Film with Variable Cross-Sectional Properties"). Joseph Fuisz Esq., managing member for Fuisz Pharma, explained: "It is understood that bi-layer film compositions can offer improved buccal absorption characteristics by retarding the drug that is lost to...
MIAMI, Sept. 7, 2012 /PRNewswire/ -- Fuisz (www.fuisz.com) today announced the issuance of US Patent 8,255,279 ("Method and Apparatus for Permitting Stage Door Access to On-Line Vendor Information"). A related case, U.S. Patent 7,962,367, issued last year. Joseph Matus Fuisz, Managing Member of Fuisz, stated, "This patent covers a system wherein product supplier to access consumer preference information - such as shopping trends -- from an e-commerce web site. In view of the...
